MedImmune takes on managed care

Products to prevent disease sound perfect for the managed care environment - until it comes time for someone to pay for them.

MedImmune Inc.'s RespiGam specialty immune globulin to prevent respiratory syncytial virus in high-risk infants was approved last January, and the company has had all year to prepare for a full launch during this fall's RSV season. The company is tackling the managed care problem directly by working to enlist managed care providers on its side. With 60 million patients enrolled in HMOs this year, a number expected to rise to 70 million in 1997 as Medicare pushes enrollment of seniors, companies have growing incentives to devise strategies for enlisting managed care companies on their side.